GSK to advance mRNA flu vaccine to late-stage trial

GSK will advance its mRNA-based seasonal influenza vaccine into late-stage trials after mid-stage data showed stronger immune responses than currently approved standard- and high-dose shots. The company is positioning the program as a potential step-up in efficacy versus existing formulations, supporting a constructive outlook for pipeline progress.